Financial Performance - The estimated net profit attributable to shareholders is projected to be between 242 million and 296 million CNY, representing a year-on-year growth of 6.00% to 29.65%[2] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 232 million and 286 million CNY, with a year-on-year growth of 3.77% to 27.93%[2] Business Operations - The company's medical consumables centralized operation (SPD) business has maintained rapid growth, contributing to enhanced overall profitability[4] Financial Management - The company has optimized its financial structure, resulting in a year-on-year decrease in interest-bearing debt and a reduction in financing costs, positively impacting net profit[4] - The performance forecast is based on preliminary calculations by the finance department and has not yet been audited[5]
建发致新(301584) - 2025 Q4 - 年度业绩预告